Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 6/20 | 0.74 |
| ▸ | PTGS2 known ✓ | P35354 | 6/20 | 0.74 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.74 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.74 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.74 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | THPO | P40225 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketoprofen SCHEMBL20969451 | 1.00 | PTGS1 (0.74) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ketoprofen SCHEMBL7624389 | 0.88 | PTGS2 (0.59) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| R-Ketoprofen SCHEMBL29353694 | 0.86 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ketoprofen SCHEMBL8754790 | 0.86 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Dexketoprofen SCHEMBL29396875 | 0.86 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| R-Ketoprofen SCHEMBL195303 | 0.86 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ketoprofen SCHEMBL3843886 | 0.86 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ketoprofen SCHEMBL679920 | 0.86 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Ketoprofen SCHEMBL16757741 | 0.86 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| Dexketoprofen SCHEMBL66987 | 0.86 | PTGS1 (1.00) | PTGS1PTGS2CXCR1CXCR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190859-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2024-06-13 | — | — | US | disclosed |
| US-11970490-B2 | Stable heavy isotopes in amide functional groups and uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-04-30 | — | — | US | disclosed |
| US-20240000761-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2024-01-04 | — | — | US | disclosed |
| EP-4126815-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20220002285-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-01-06 | — | — | US | disclosed |
| WO-2021189143-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-09-30 | — | — | WO | disclosed |
| US-20210220510-A1 | Cellularised Dressing and Method for Producing Same | URGO RECHERCHE INNOVATION ET DEVELOPPEMENT (FR) | 2021-07-22 | — | — | US | disclosed |
| US-20200375926-A1 | INJECTABLE RESINIFERATOXIN | AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT | 2020-12-03 | — | — | US | disclosed |
| US-10821152-B2 | Methods, agents and compositions for treatment of inflammatory conditions | Betanien Hospital (NO) | 2020-11-03 | — | — | US | disclosed |
| US-20200038324-A1 | WAX FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF | Foamix Pharmaceuticals | 2020-02-06 | — | — | US | disclosed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004043976-A2 | MKK7GAMMA1 NUCLEIC ACIDS AND POLYPEPTIDES | WARNER-LAMBERT COMPANY LLC (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20030008008-A1 | Fast dissolving orally consumable films | JOHNSON & JOHNSON CONSUMER INC. | 2003-01-09 | — | — | US | disclosed |
| EP-1235618-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017568-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | disclosed |
| US-5985843-A | PHARMACEUTICAL PREPARATION THAT CONTAINS SUCRALFATE IN THE PRESENCE OF ANOTHER DRUG IN SUCH A WAY THAT THE ANOTHER DRUG IS IMMEDIATELY RELEASED WITHOUT BEING ADSORBED ON OR TRAPPED BY THE SUCRALFATE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-11-16 | — | — | US | disclosed |
| US-5766521-A | Process for obtaining cristallized pearls exhibiting the phenomenon of supercooling | RHONE-POULENC CHIMIE (FR) | 1998-06-16 | — | — | US | disclosed |
| EP-0823255-A1 | PHARMACEUTICAL COMPOSITION CONTAINING SUCRALFATE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-02-11 | — | — | EP | disclosed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | disclosed |
| US-4393067-A | Nicotinoyl esters for analgesic and anti-inflammatory treatment | D AND D SRL (IT) | 1983-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821152-B2 | Methods, agents and compositions for treatment of inflammatory conditions | GNRHR, SHBG, TNF | PTGS1 134/4885PTGS2 259/4885CXCR1 221/4885 |
| US-20220002285-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | AADAC, SLC10A1, SLC3A2 | PTGS1 2269/4885PTGS2 2875/4885CXCR1 2410/4885 |
| US-11970490-B2 | Stable heavy isotopes in amide functional groups and uses thereof | AADAC, SLC10A1, SLC3A2 | PTGS1 2269/4885PTGS2 2875/4885CXCR1 2410/4885 |
| US-20240000761-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | AADAC, SLC10A1, SLC3A2 | PTGS1 2269/4885PTGS2 2875/4885CXCR1 2410/4885 |
| US-20200038324-A1 | WAX FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF | CUTA, LIPA, MGLL | PTGS1 1632/4885PTGS2 1736/4885CXCR1 1232/4885 |
| US-20240190859-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | AADAC, SLC10A1, SLC3A2 | PTGS1 2269/4885PTGS2 2875/4885CXCR1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.